From Disease Biology to Individualized Management: Where Is Psoriasis Care Headed?

This Q&A explores what individualized psoriasis management means today, how evolving insights into disease heterogeneity may inform care, and the opportunities and current limitations of biomarkers and precision approaches to treatment selection.

What Does “Individualized Management” Mean in Psoriasis Today?

Individualized psoriasis management is routine in clinical practice, although treatment decisions are still guided mainly by clinical and patient-level factors rather than molecular profiling or validated predictive biomarkers.^1,2 Treatment decisions are commonly informed by multiple factors, including disease severity, extent of skin involvement, and lesion location. The presence of comorbidities further contributes to disease burden and influences therapeutic decisions.^1-3 Treatment selection can additionally be guided by previous treatment experience and response, patient preferences, lifestyle considerations, and treatment goals as well as by practical factors such as route of administration, dosing frequency, and overall treatment burden.¹

What Can Disease Heterogeneity Tell Us About Differences Among Patients?

Psoriasis is a highly heterogeneous disease characterized by considerable variability in morphology, distribution, severity, and symptom presentation. This heterogeneity extends beyond observable clinical features, such as age of disease onset and lesion characteristics, to include differences in genetic susceptibility and environmental triggers, such as infection, stress, and trauma, that contribute to disease initiation.^1,4,5 More recently, research has shown that variability also exists at the biological level, with differences in the immune cell populations that drive disease pathogenesis, and in the composition of the skin microenvironment, further highlighting the complex and individualized nature of psoriasis.^6,7 

How Is Evolving Disease Biology Changing the Way We Think About Psoriasis Management?

Advances in transcriptomic and proteomic analyses have expanded the overall understanding of psoriasis biology.^6,7 While the interleukin (IL)-23/IL-17 axis has a well-established central role in psoriasis pathogenesis, it is now recognized as part of a broader inflammatory network involving multiple immune cell populations, cytokines, and signaling pathways.^7,8 Psoriasis is known to be a heterogeneous, systemic inflammatory disorder characterized by reciprocal interactions between immune cells and keratinocytes that perpetuate chronic inflammation.^6,7 

Growing insights into intracellular signaling mechanisms, including tyrosine kinase 2 (TYK2)-mediated pathways, have further refined the biological framework of psoriasis. At the same time, molecular and cellular studies continue to reveal biological variability among patients that may not be apparent from clinical presentation alone.^6,7,9 Together, these findings highlight that seemingly similar clinical observations of disease may reflect important differences in underlying cellular and molecular processes.

Can Biomarkers Tell Us Which Treatment Is Most Likely to Work for an Individual Patient?

Research continues to evaluate genetic markers, transcriptomic and proteomic signatures, immune and cytokine profiles, and other candidate biomarkers that may help explain variation in psoriasis phenotype, disease course, and treatment response.^6,10 These efforts have identified promising molecular signals and potential endotypes, including susceptibility loci, differences in gene expression, and exploratory immune pathway markers.^5,6,11,12 However, these findings have not yet translated into validated predictive biomarkers that reliably guide prospective treatment selection for an individual patient. Individualized care today remains grounded in clinical and patient characteristics, such as disease severity, body surface area or location, comorbidities, treatment history, and quality-of-life impact.¹ Precision medicine would add validated biological information capable of predicting outcomes or treatment response, though biomarker-guided treatment is not yet available in routine psoriasis management.^6,13 

What Could the Next Stage of Individualized Psoriasis Management Look Like?

The next stage of individualized psoriasis management may involve more refined integration of biological, clinical, and patient-reported information. Continued research may help better characterize psoriasis heterogeneity, including proposed molecular endotypes, predictive biomarkers, treatment-response patterns, and factors associated with specific disease trajectories or comorbidities.¹³ As evidence evolves, biological insights may add another layer to treatment planning, but they should be understood as complementing and not replacing clinical judgment, shared decision-making, and patient-centered care.

Final Takeaway

Advances in disease biology are providing an increasingly nuanced understanding of psoriasis and the factors that contribute to patient variability. However, while greater biological precision may eventually add another layer to individualized disease management, the patient, rather than any single pathway, biomarker, or molecular subtype, should remain at the center of treatment decisions.
 

References

1. Mehta S, Sathe NC. Plaque psoriasis. In: StatPearls. StatPearls Publishing; 2025. Updated September 14, 2025. Accessed August 17, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430879/ 
2. Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Sig Transduct Target Ther. 2023;8(1):437. doi:10.1038/s41392-023-01655-6
3. Nong Y, Han G, Hawkes JE. Expanding the psoriasis framework: immunopathogenesis and treatment updates. Cutis. 2024;113(2):82-91. doi:10.12788/cutis.0949
4. Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392-398. doi:10.5114/reum.2018.80718
5. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-ii23. doi:10.1136/ard.2004.033217
6. Cui N, Xu X, Zhou F. Single-cell technologies in psoriasis. Clin Immunol. 2024;264:110242. doi:10.1016/j.clim.2024.110242
7. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis — current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164-191. doi:10.1007/s12016-024-08991-7
8. Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase–signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869 
9. Martin G. Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417-435. doi:10.1007/s13555-022-00878-9 
10. Zhang S, Chang M, Zheng L, et al. Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis. Front Immunol. 2024;15:1326502. doi:10.3389/fimmu.2024.1326502
11. Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:25-33. doi:10.2147/PTT.S328447
12. Ma F, Plazyo O, Billi AC, et al. Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis. Nat Commun. 2023;14(1):3455. doi:10.1038/s41467-023-39020-4
13. Chandran V, Liao W, de Vlam K. Biomarkers in psoriasis and psoriatic arthritis: where are we now? J Rheumatol. 2024;51(Suppl 2):74-76. doi:10.3899/jrheum.2024-0260
14. Rider A, Grantham HJ, Smith GR, et al. Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity. Commun Med (Lond). 2026;6(1):65 doi:10.1038/s43856-025-01325-4